Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Abbott and DexCom depend heavily on continuous glucose monitoring (CGM) device sales. Vertex is developing therapies that could cure type 1 diabetes. If Vertex is successful, the CGM market could be ...
Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results